A study to assess the Patient navigation and symptom reporting with patient reported outcome in lung cancer patient.

A two-arm randomized open label prospective parallel design Phase III clinical trial to evaluate the efficacy of a multidisciplinary patient navigation program along with symptom-monitoring with patient-reported outcomes in advanced lung cancer patients.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/02/023511

Enrollment

150

Registered

2020-02-24

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C399- Malignant neoplasm of lower respiratory tract, part unspecified

Interventions

Intervention1: Navigator: The overall job of the patient navigator will be to help coordinate the care of the patient, to function as a go-between for the doctor and the patient, and to help the patie

Eligibility

Inclusion criteria

Inclusion criteria: 1.Suspected/diagnosed lung cancer patient 2.Planned for palliative intent therapy at Tata Memorial Center 3.Willing to give written informed consent

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Functional Assessment of Cancer Therapyâ??Lung (FACT-L) Quality of Life measureTimepoint: FACT & QOL at Baseline & every 12 weeks.	—

Secondary

Measure	Time frame
1. Time to initiation of cancer treatment. 2.treatment completion 3. progression-free survival 4. number of emergency visits or unplanned visits, dose intensity 5.time to deterioration of ECOG performance status, 6. Treatment adherence 7. symptom control between the two arms 8.percentage survival 9.overall survival (OS). Timepoint: 1. At Initiation 2. At end of 4 cycles or 3 months 3. PFE at Progression 4. At progression 5. At Progression 6. At Progression 7. At Progression 8. At 1 year 9. At death	—

Measure

Time frame

1. Time to initiation of cancer treatment. 2.treatment completion 3. progression-free survival 4. number of emergency visits or unplanned visits, dose intensity 5.time to deterioration of ECOG performance status, 6. Treatment adherence 7. symptom control between the two arms 8.percentage survival 9.overall survival (OS). Timepoint: 1. At Initiation 2. At end of 4 cycles or 3 months 3. PFE at Progression 4. At progression 5. At Progression 6. At Progression 7. At Progression 8. At 1 year 9. At death

—

Countries

India

Contacts

Public ContactDr Vanita Noronha

Tata Memorial Hospital

vanita.noronha@gmail.com9769328047

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026